Healthcare / Diagnostics & ResearchStockholm
$0.20
+0.00 (+1.74%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-96.8M · quality 79.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
15/100
F
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$138M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-225.3%
↓Gross Margin
80.1%
↑Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-15.7%
FCF CAGR
—
FCF margin
-12256.8%
FCF / Net income
0.58x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $685000.0 · net income $-145.9M · FCF $-84.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $685000.00 | $685000.00 | $931000.00 | $1.6M | $1.1M |
| Net Income | $-145.9M | $-145.9M | $-76.5M | $-309.4M | $-168.1M |
| EBITDA | $-141.5M | $-141.5M | $-61.3M | $-166.6M | $-141.6M |
| EPS | -0.42 | -0.42 | -0.93 | -6.18 | -2.66 |
| Gross Margin | 80.1% | 80.1% | 100.0% | -324.3% | -267.8% |
| Operating Margin | -11744.8% | -11744.8% | -11765.5% | -18832.7% | -16699.5% |
| Net Margin | -21301.5% | -21301.5% | -8221.4% | -19646.9% | -14680.5% |
| Balance Sheet | |||||
| Debt/Equity | 0.01 | 0.01 | 0.06 | 0.15 | 0.15 |
| Current Ratio | 3.05 | 3.05 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-84.0M | $-84.0M | $-96.8M | $-148.1M | $-177.2M |
| Returns | |||||
| ROE | -225.3% | -225.3% | -657.1% | -461.9% | -68.9% |
| Valuation | |||||
| P/B | 1.09 | 1.09 | 2.97 | 0.64 | 2.32 |
| Growth & Yield | |||||
| Revenue Growth | -26.4% | -26.4% | -40.9% | 37.6% | — |
| EPS Growth | 54.8% | 54.8% | 85.0% | -132.1% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-26.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.93 → -0.42
Residual
-26.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.